Genetic polymorphisms in folate and homocysteine metabolism as risk factors for DNA damage

European Journal of Human Genetics

Volumn 11, Issue 9, 2003, Pages 671-678

  Botto, Nicoletta ^a,b   Andreassi, Maria Grazia ^a   Manfredi, Samantha ^a   Masetti, Serena ^a,b   Cocci, Franca ^c   Colombo, Maria Giovanna ^a   Storli, Simona ^a   Rizza, Antonio ^a   Biagini, Andrea ^a  

^a G PASQUINUCCI HOSPITAL   (Italy)

^b SCUOLA SUPERIORE SANT ANNA   (Italy)

^c INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

Coronary artery disease; DNA damage; Folate; Homocysteine; Methionine synthase reductase; Methylenetetrahydrofolate reductase; Micronucleus test

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ADENINE; ALANINE; CYSTEINE; FOLIC ACID; GLUTAMIC ACID; GUANINE; HOMOCYSTEINE; METHIONINE SYNTHASE REDUCTASE; OXIDOREDUCTASE; THREONINE; UNCLASSIFIED DRUG;

ADULT; AMINO ACID METABOLISM; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD LEVEL; CONGENITAL DISORDER; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA DAMAGE; EPIDEMIOLOGICAL DATA; FEMALE; FOLATE METABOLISM; FREQUENCY ANALYSIS; GENETIC POLYMORPHISM; GENETIC STABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MICRONUCLEUS TEST; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE;

ADULT; ANALYSIS OF VARIANCE; CORONARY ARTERIOSCLEROSIS; DNA DAMAGE; DNA PRIMERS; FEMALE; FERREDOXIN-NADP REDUCTASE; HEREDODEGENERATIVE DISORDERS, NERVOUS SYSTEM; HOMOCYSTEINE; HUMANS; ITALY; LYMPHOCYTES; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MODELS, BIOLOGICAL; POLYMORPHISM, GENETIC;

EID: 0141590217     PISSN: 10184813     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ejhg.5201024     Document Type: Article

References (46)

1. McCully KS: Chemical pathology of homocysteine. II. Carcinogenesis and homocysteine thiolactone metabolism. Ann Clin Lab Sci 1994; 24: 27-59.
2. Fonseca V, Guba SC, Fink LM: Hyperhomocysteinemia and the endocrine system: implications for atherosclerosis and thrombosis. Endocr Rev 1999; 20: 738-759.
3. Breteler MM: Vascular involvement in cognitive decline and dementia. Epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. Ann NY Acad Sci 2000; 903: 457-465.
4. Miller JW: Homocysteine, Alzheimer's disease, and cognitive function. Nutrition 2000; 16: 675-677.
5. Wenstrom KD, Johanning GL, Owen J, Johnston KE, Acton S, Tamura T: Role of amniotic fluid homocysteine level and of fetal 5,10-methylenetetrahydrafolate reductase genotype in the etiology of neural tube defects. Am J Med Genet 2000; 90: 12-16.
6. Kang SS, Wong PW, Susmano A, Sora J, Norusis M, Ruggie N: Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991; 48: 536-545.
7. Frosst P, Blom HJ, Milos R et al: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113.
8. Jacques PF, Bostom AG, Williams RR et al: Relation between folate status a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93: 7-9.
9. Christensen B, Frosst P, Lussier-Cacan S et al: Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. Arterioscler Thromb Vasc Biol 1997; 17: 569-573.
10. Brattstrom L, Wilcken DE, Ohrvik J, Brudin L: Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 1998; 98: 2520-2526.
11. Andreassi MG, Botto N, Cocci F et al: Methylentetrahydrofolate reductase gene C677T polymorphism, homocysteine, vitamin B12 and DNA damage in coronary artery disease. Hum Genet 2003; 112: 171-177.
12. van der Put NM, Gabreels F, Stevens EM et al: A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects. Am J Hum Genet 1998; 62: 1044-1051.
13. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R: A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998; 64: 169-172.
14. Chango A, Boisson F, Barbe F et al: The effect of 677C→T and 1298A→C mutations on plasma homocysteine and 5,10-methylenetetrahydrofolate reductase activity in healthy subjects. Br J Nutr 2000; 83: 593-596.
15. Hanson NQ, Aras O, Yang F, Tsai MY: C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: incidence and effect of combined genotypes on plasma fasting and post-methionine load homocysteine in vascular disease. Clin Chem 2001; 47: 661-666.
16. Friso S, Girelli D, Trabetti E et al: A1298C methylenetetrahydrofolate reductase mutation and coronary artery disease: relationships with C677T polymorphism and homocysteine/folate metabolism. Clin Exp Med 2002; 2: 7-12.
17. Wilson A, Platt R, Wu Q et al: A common variant in methionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida. Mol Genet Metab 1999; 67: 317-323.
18. Hobbs CA, Sherman SL, Yi P et al: Polymorphisms in genes involved in folate metabolism as maternal risk factors for Down syndrome. Am J Hum Genet 2000; 67: 623-630.
19. O'Leary VB, Parle-McDermott A, Molloy AM et al: MTRR and MTHFR polymorphism: link to Down syndrome? Am J Med Genet 2002; 107: 151-155.
20. Sambrook J, Fritsch EF, Maniatis T (eds): Molecular cloning: a laboratory manual, 2nd edn. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
21. Botto N, Rizza A, Colombo MG et al: Evidence for DNA damage in patients with coronary artery disease. Mutat Res 2001; 493: 23-30.
22. Fenech M. The in vitro micronucleus technique. Mutat Res 2000; 455: 81-95.
23. Van Schooten FJ, Hirvonen A, Maas LM et al: Putative susceptibility markers of coronary artery disease: association between VDR genotype, smoking, and aromatic DNA adduct levels in human right atrial tissue. FASEB J 1998; 12: 1409-1417.
24. Tribouilloy CM, Peltier M, Iannetta Peltier MC, Trojette F, Andrejak M, Lesbre JP: Plasma homocysteine and severity of thoracic aortic atherosclerosis. Chest 2000; 118: 1685-1689.
25. Schnyder G, Pin R, Roffi M, Flammer Y, Hess OM: Association of plasma homocysteine with the number of major coronary arteries severely narrowed. Am J Cardiol 2001; 88: 1027-1030.
26. Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE: Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 2001; 22: 195-201.
27. Friedman G, Goldschmidt N, Friedlander Y et al: A common mutation A1298C in human methylenetetrahydrofolate reductase gene: association with plasma total homocysteine and folate concentrations. J Nutr 1999; 129: 1656-1661.
28. Gaughan DJ, Kluijtmans LA, Barbaux S et al: Corrigendum to 'The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations'. Atherosclerosis (in press).
29. Brown CA, McKinney KQ, Kaufman JS, Gravel RA, Rozen R: A common polymorphism in methionine synthase reductase increases risk of premature coronary artery disease. J Cardiovasc Risk 2000; 7: 197-200.
30. Thambyrajah J, Townend JN: Homocysteine and atherothrombosis - mechanisms for injury. Eur Heart J 2000; 21: 967-974.
31. Fenech MF, Dreosti IE, Rinaldi JR: Folate, vitamin B12, homocysteine status and chromosome damage rate in lymphocytes of older men. Carcinogenesis 1997; 18: 1329-1336.
32. Fenech M, Aitken C, Rinaldi J: Folate, vitamin, B12 homocysteine status and DNA damage in young Australian adults. Carcinogenesis 1998; 19: 1163-1171.
33. Yi P, Melnyk S, Pogribna M, Pogribny IP, Hine RJ, James SJ: Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypomethylation. J Biol Chem 2000; 275: 29318-29323.
34. Crott J, Fenech M: Preliminary study of the genotoxic potential of homocysteine in human lymphocytes in vitro. Mutagenesis 2001; 16: 213-217.
35. Fenech M: The role of folic acid and Vitamin B12 in genomic stability of human cells. Mutat Res 2001; 475: 57-67.
36. Dong C, Yoon W, Goldschmidt-Clermont PJ: DNA methylation and atherosclerosis. J Nutr 2002; 132: 2406S-2409S.
37. Duthie SJ, Narayanan S, Brand GM, Pirie L, Grant G: Impact of folate deficiency on DNA stability. J Nutr 2002; 132: 2444S-2449S.
38. Friso S, Choi SW: Gene-nutrient interactions and DNA methylation. J Nutr 2002; 132: 2382S-2387S.
39. Andreassi MG: Coronary atherosclerosis and somatic mutations: an overview of the contributive factors for oxidative DNA damage. Mutat Res 2003; 543: 67-86.
40. Loscalzo J: The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996; 98: 5-7.
41. Guttenbach M, Schmid M: Exclusion of specific human chromosomes into micronuclei by 5-azacytidine treatment of lymphocyte cultures. Exp Cell Res 1994; 211: 127-132.
42. Xu GL, Bestor TH Bourc'his D et al: Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature 1999; 402: 187-191.
43. Hiltunen MO, Turunen MP, Hakkinen TP et al: DNA hypomethylation and methyltransferase expression in atherosclerotic lesions. Vasc Med 2002; 7: 5-11.
44. Laukkanen MO, Mannermaa S, Hiltunen MO et al: Local hypomethylation in atherosclerosis found in rabbit ec-sod gene. Arterioscler Thromb Vasc Biol 1999; 19: 2171-2178.
45. Stern LL, Mason JB, Selhub J, Choi SW: Genomic DNA hypomethylation, a characteristic of most cancers, is present in peripheral leukocytes of individuals who are homozygous for the C677T polymorphism in the methylenetetrahydrofolate reductase gene. Cancer Epidemiol Biomarkers Prev 2000; 9: 849-853.
46. Friso S, Choi SW, Girelli D et al: A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci USA 2002; 99: 5606-5611.